Menu

  • Products
  • MRI Information
  • Reimbursement
  • Medtronic Academy

    • Restore quality of life with the NURO™ system for bladder incontinence.1-5

    More than 43 million adults in the United States suffer from overactive bladder (OAB).6,7 Percutaneous tibial neuromodulation (PTNM) using the Medtronic NURO™ system is a simple, effective therapy that targets the nerves that control your bladder.1,2

    1 in 6
    US adults

    experiences symptoms of overactive bladder.6

    NURO™ system for bladder control

    PTNM therapy can help restore bladder function† without the side effects of medication‡ or the potential need to self-catheterize.1,2

    The Medtronic NURO™ system is a safe, effective, office-based PTNM treatment for OAB.1-5,7-9 Delivered with an external neurostimulator, PTNM expands your options for OAB patients.

    How the NURO system works

    The NURO™ system delivers electrical pulses through a needle to stimulate the afferent fibers of the tibial nerve that runs posterior to the medial malleolus and extends to the sacral nerve plexus. The sacral nerve controls communication between the brain and bladder.10,11

    The NURO™ II device is used for percutaneous neurostimulation therapy.

    Candidates for PTNM

    Candidates for PTNM therapy include patients who:

    • Have an overactive bladder with symptoms of urinary urgency, urinary frequency, or urge incontinence
    • Are seeking an alternative to oral medications
    • Prefer an office-based treatment
    • Are not a candidate for sacral neuromodulation (SNM)
    • Need a lower-body MRI
    • Are unwilling or unable to tolerate the potential need for self-catheterization

    The most common side effects of PTNM are temporary and include mild pain or skin inflammation at or near the stimulation site.

    A mature couple holding hands while walking and laughing outside.

    Clinical data: A safe option to restore bladder function†

    PTNM delivered by the Medtronic NURO™ system, is a safe, minimally invasive, and effective OAB treatment option.3–9

    In 2018, the RESET study was the first to establish clinical evidence for the NURO™ system, determining that PTNM delivered by the NURO™ device can significantly reduce urge incontinence (UI) episodes for drug-naïve OAB patients. Prior to RESET, many published studies provided evidence supporting the safety and efficacy of PTNM for OAB patients, delivered by a different (but equivalent) device than NURO.5–6

    90%

    Reduction in the proportion of patients who reported having severe or very severe problems with OAB per the patient perception of bladder condition scale12

    About
    70%

    Reduction in urge urinary incontinence (UUI) episodes per day at completion of 12 PTNM sessions8

    Significant improvements

    in total health-related quality of life and its subscales, including concern, coping, sleep, social, and symptom bother◊,12

    Access Medtronic Connect

    Order NURO™ kits online.

    Register now

    Contact a representative

    Connect with your Medtronic rep for a starter kit and more.

    Reach out

    Education and training

    See how to deliver therapy with on-demand materials.

    Visit Medtronic Academy

    † ”Restored bladder” function is defined as a measurable reduction in urinary frequency and/or urinary incontinence episodes following treatment.

    ‡ The most common side effects are temporary and include mild pain or skin inflammation at or near the stimulation site.

    § While the NURO device was not used in the Peters study, since it delivers equivalent stimulation as the device used, a user can expect similar performance.

    ◊ Evaluated using the Overactive Bladder Symptom Quality of Life Questionnaire (OAB-q).

    1. Peters KM, Macdiarmid SA, Wooldridge LS, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009;182(3):1055–1061.
    2. Peters KM, Carrico DJ, Perez-Marrero RA, et al. Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010;183(4):1438–1443.
    3. Finazzi-Agrò E, Campagna A, Sciobica F, et al. Posterior tibial nerve stimulation: is the once-a-week protocol the best option? Minerva Urol Nefrol. 2005;57(2):119–123.
    4. Finazzi-Agrò E, Petta F, Sciobica F, et al. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol. 2010;184(5):2001–2006.
    5. Stewart WF, Van Rooyen JB, Cundiff GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003;20(6):327–336.
    6. US Census Bureau 2020. US adult and under-age-18 populations: 2020 census. https://www.census.gov/library/visualizations/interactive/adult-and-under-the-age-of-18-populations-2020-census.html. Accessed June 20, 2022.
    7. Kobashi K, Margolis E, Sand P, et al. Prospective study to evaluate quality of life with percutaneous tibial neuromodulation in drug-naïve patients with overactive bladder syndrome. Presented at the 2018 Annual Meeting of the International Continence Society. 
    8. Kobashi K, Khandwala S, MacDiarmid S, et al. A prospective study to evaluate efficacy with the NURO percutaneous tibial neuromodulation system in drug naïve patients with overactive bladder syndrome (OAB). Presented at the American Urological Association 2018 Annual Meeting. J Urol. 2018;199(4) Supplement, Page e987.
    9. Kobashi K, Nitti V, Margolis E, et al. A prospective study to evaluate efficacy using the Nuro percutaneous tibial neuromodulation system in drug-naïve patients with overactive bladder syndrome. Urol. 2019;131:77–82.
    10. Chancellor MB, Chartier-Kastler EJ. Principles of sacral nerve stimulation (SNS) for the treatment of bladder and urethral sphincter dysfunctions. Neuromod. 2000;3(1):15–26.
    11. Leng WW, Chancellor MB. How sacral nerve stimulation neuromodulation works. Urol Clin North Am. 2005;32:11–18.
    12. Sand P, Kobashi K, Margolis E, et al. Patient reported outcomes with percutaneous tibial neuromodulation (PTNM) therapy in drug naive patients with overactive bladder (OAB) syndrome. Presented at the American Urogynecologic Society 2018 Annual Scientific Meeting.